We are working closely alongside kidney experts and patient advocates as we advance precision medicines for people, like you, living with kidney disease. Our goal is to introduce a new era for the treatment of kidney diseases, bringing novel therapies designed specifically to target the root cause of your disease. A growing number of diseases are already being treated with precision medicines. We believe it is time to bring this innovation to the kidney community, too.
On this page, you can learn more about our patient-focused initiatives and find helpful resources.
As we advance precision kidney medicines, we are committed to being a long-term partner to the inspiring community of patients and caregivers living with and managing FSGS and other kidney diseases. We have launched The Halo Initiative as a platform aimed at ensuring patients’ experiences are understood, that their individual and collective voices are heard, and that their perspectives are invited and embraced.
Our initial effort of The Halo Initiative is The Halo Survey, through which we will be exploring and elucidating the impact of current medications and treatment options on patients’ health and quality of life – as reported specifically by patients.
We have designed the Halo Survey in partnership with our Patient Advisory Board. To our knowledge, this will be the first comprehensive patient perspective survey of its kind in the kidney disease space. We plan to use the survey’s findings to educate researchers, clinicians and other stakeholders about kidney disease patients’ real-world experiences with treatment options.
Take ten minutes to take the Halo Survey. The first 250 participants will receive $25 Amazon Gift Card if they are eligible.
Please consider participating in this survey as we work to raise awareness of the need for more effective treatment solutions for people living with kidney disease.
We created our Patient Advisory Board to foster a cohesive and productive partnership with the patient community. Our advisors enable us to advance our mission to deliver disease-modifying precision medicines that bring hope and renewed quality of life to people living with kidney diseases.
Because of the current lack of therapeutic options, many people with kidney disease follow the same trajectory. They progress from disease onset to end-stage kidney disease and, ultimately, dialysis and transplantation, significantly impacting their quality of life.
The halo symbolizes our goal to protect people with kidney disease from following this path by delivering disease-modifying precision medicines.
Learn more about some of the organizations working on behalf of you and your loved ones:
The purpose of our Phase 2 trial, TRACTION-2, is to determine if our once-daily, oral, investigational precision medicine, GFB-887, is beneficial for people with high levels of protein in their urine due to focal segmental glomerulosclerosis (FSGS), diabetic nephropathy (DN) or treatment resistant minimal change disease (TR-MCD). Patients participating in TRACTION-2 may be eligible to participate in an open-label, long-term extension trial.
To learn more about TRACTION-2, visit TractionClinicalTrial.com or clinicaltrials.gov
The purpose of our Phase 1 trial is to determine if our investigational precision medicine, GFB-024, is safe and well tolerated in overweight and obese healthy volunteers.
For more information about the clinical trial design, please visit: www.clinicaltrials.gov (NCT04880291).
It is our duty to carefully evaluate the safety and efficacy of any of our investigational precision medicine product candidates. We believe that clinical trials are the best and most appropriate way to do that. The process is a collaborative effort, and we will work closely with researchers, physicians, clinical trial site teams, people living with kidney diseases and their families to conduct our studies efficiently and effectively. When successful, data from these studies form the basis of regulatory (i.e. U.S. Food and Drug Administration, European Medicine Agency, or other similar regulatory agencies) approvals, which ensure the most equitable and sustainable access to our precision medicines for the people who need them.
We know that people living with kidney diseases and their families are counting on us to potentially extend and improve their quality of life. Given this, we understand that some people living with kidney diseases and their families may be interested in accessing our investigational precision medicine product candidates prior to regulatory approval, and outside of the clinical trial setting, through an expanded access program (sometimes referred to as “early access” or “compassionate use”). Goldfinch Bio does not offer programs that allow access to our precision medicine product candidates prior to regulatory approval. For now, participating in a clinical trial is the only way to access our precision medicine product candidates.
More information about Goldfinch Bio’s current clinical trials is available above in the section titled “Information about our ongoing clinical trials.” If you have additional questions, please talk to your doctor or contact earlyaccessprogram@goldfinchbio.com. We plan to acknowledge receipt of requests sent to this email address within five business days.